Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.

The article focuses on a study related to exploring whether single nucleotide polymorphism (SNP) will be clinical outcome predictive in multiple myeloma (MM) or not, using autologous stem cell support and high-dose melphalan. Topics discussed include assumption of polygenic phenomenon for MM risk; treatment of patients with thalidomide monotherapy; and use of SNP in TP53 is predictive of clinical outcome in MM.